Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.31 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.31 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6781867 | 1.00 | CHRNB2 (0.35) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL6137253 | 0.87 | — | — | |
| SCHEMBL6137258 | 0.87 | — | — | |
| SCHEMBL6781869 | 0.80 | CHRNB2 (0.32) | CHRNB2CHRNA4 | |
| Trifluoroacetic Acid SCHEMBL6703765 | 0.78 | KDM4E (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL6792658 | 0.78 | KDM4E (0.31) | — | |
| Trifluoroacetic Acid SCHEMBL6705344 | 0.77 | — | — | |
| Trifluoroacetic Acid SCHEMBL6785439 | 0.77 | — | — | |
| Trifluoroacetic Acid SCHEMBL6704433 | 0.76 | KDM4E (0.30) | — | |
| SCHEMBL6136828 | 0.71 | HRH3 (0.46) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794405-B2 | Alicyclic imidazoles as H3 agents | MERCK & CO., INC. | 2004-09-21 | — | — | US | disclosed |
| US-20040029943-A1 | Novel alicylic imidazoles as H3 agents | MERCK SHARP & DOHME CORP. | 2004-02-12 | — | — | US | disclosed |
| US-20020042400-A1 | Novel alicyclic imidazoles as H3 agents | GLIATECH, INC. | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029943-A1 | Novel alicylic imidazoles as H3 agents | HRH3, HRH2, HRH4 | CHRNB2 465/4885CHRNA4 264/4885CHRNA3 107/4885 |
| US-20020042400-A1 | Novel alicyclic imidazoles as H3 agents | HRH3, HRH2, HRH4 | CHRNB2 403/4885CHRNA4 164/4885CHRNA3 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.